Trial Profile
A Multicenter, Open-Label, Phase 1 Trial of SHR3162 Given Orally to Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fuzuloparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Atridia; Jiangsu Hengrui Medicine Co.
- 18 Sep 2019 Status changed from active, no longer recruiting to completed.
- 07 Aug 2019 Planned End Date changed from 1 Jul 2019 to 1 Sep 2019.
- 19 Feb 2019 Planned End Date changed from 1 Jun 2019 to 1 Jul 2019.